{
    "paper_id": "PMC7194245",
    "metadata": {
        "title": "COVID-19 pandemic and the risk of infection in multiple sclerosis patients on disease modifying therapies: \u201cwhat the bleep do we know?\u201d",
        "authors": [
            {
                "first": "Salman",
                "middle": [],
                "last": "Mansoor",
                "suffix": "",
                "email": "salmanmansoor.dr@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Siobhan",
                "middle": [],
                "last": "Kelly",
                "suffix": "",
                "email": "siobhankelly77@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Kevin",
                "middle": [],
                "last": "Murphy",
                "suffix": "",
                "email": "dkevinmurphy@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Aine",
                "middle": [],
                "last": "Waters",
                "suffix": "",
                "email": "aine.waters2@hse.ie",
                "affiliation": {}
            },
            {
                "first": "Nauman",
                "middle": [
                    "Saleem"
                ],
                "last": "Siddiqui",
                "suffix": "",
                "email": "drnaumansaleem@gmail.com",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Coronavirus (COVID-19) has been termed as a global pandemic by the World Health Organization after being first diagnosed in December 2019 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen). The number of people infected with the virus is rising at an exponential rate with data from the World Health Organization (WHO) being updated regularly (https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports). The mortality rate is reported to be between 1 and 5% [1\u20133].",
            "cite_spans": [
                {
                    "start": 520,
                    "end": 521,
                    "mention": "1",
                    "ref_id": "BIBREF0"
                },
                {
                    "start": 522,
                    "end": 523,
                    "mention": "3",
                    "ref_id": "BIBREF7"
                }
            ],
            "section": "Background",
            "ref_spans": []
        },
        {
            "text": "There is a growing concern in physicians across specialities as the situation is evolving. A practicing neurologist is facing a difficult clinical decision in relation to disease modifying therapies in multiple sclerosis and to the risk of COVID-19.",
            "cite_spans": [],
            "section": "Background",
            "ref_spans": []
        },
        {
            "text": "The coronavirus that is linked to COVID-19 is from a family of Betacoronavirus which is from the same subgenus that caused the severe acute respiratory syndrome (SARS) virus. There is a structural similarity between the receptor-binding sites. Angiotensin-converting enzyme 2 (ACE-2), for viral entry, is the proposed binding region [4].",
            "cite_spans": [
                {
                    "start": 334,
                    "end": 335,
                    "mention": "4",
                    "ref_id": "BIBREF8"
                }
            ],
            "section": "Virology",
            "ref_spans": []
        },
        {
            "text": "The cytokine response to COVID-19 yielded a rise in inflammatory cytokines (tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-2R, and IL-6) [5].",
            "cite_spans": [
                {
                    "start": 139,
                    "end": 140,
                    "mention": "5",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "Immune response in COVID-19",
            "ref_spans": []
        },
        {
            "text": "Similarly, the cell response in COVID-19 patients showed a decrease in lymphocyte subsets B cells, T cells, and natural killer cells [5]. There was a lower level of helper T cells and memory helper T cells while an increased percentage of na\u00efve helper T cells in patients who had severe disease [5]. Patients with COVID-19 also have lower level of regulatory T cells, and more obviously damaged in severe cases [5].",
            "cite_spans": [
                {
                    "start": 134,
                    "end": 135,
                    "mention": "5",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 296,
                    "end": 297,
                    "mention": "5",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 412,
                    "end": 413,
                    "mention": "5",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "Immune response in COVID-19",
            "ref_spans": []
        },
        {
            "text": "Both the rise in inflammatory cytokines and decrease in cell counts were related to the severity of the disease [5].",
            "cite_spans": [
                {
                    "start": 113,
                    "end": 114,
                    "mention": "5",
                    "ref_id": "BIBREF9"
                }
            ],
            "section": "Immune response in COVID-19",
            "ref_spans": []
        },
        {
            "text": "Undertaking HSCT may pose a significant risk to the patient and should be deferred at present considering the risk of serious COVID-19-related infection (https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf).",
            "cite_spans": [],
            "section": "Hematopoietic stem cell transplantation ::: Disease modifying therapies",
            "ref_spans": []
        },
        {
            "text": "In relation to active COVID-19 infection, a discontinuation or delay of any form of disease modifying therapy should be considered (https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf).",
            "cite_spans": [],
            "section": "Active COVID-19 infection ::: Disease modifying therapies",
            "ref_spans": []
        },
        {
            "text": "The current recommendation by the Association of British Neurologists (ABN) lacks class 1 evidence (https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf). The COVID-19 pandemic at present is expanding at an alarming rate, which may put these multiple sclerosis patients at a higher risk due to their immune status. The data from the World Health Organization (WHO) has not yet been translated in relation to this cohort of COVID-19 patients who are on disease modifying therapies. The risk estimate for the multiple sclerosis patients therefore still remains unknown.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "We recommend a careful consideration of disease modifying therapies in the current health crisis which is still unfolding. In relation to multiple sclerosis, we strongly urge clinicians to educate patients on disease modifying therapies and a potential risk of COVID-19. Patients should be urged to follow strict preventative measures and if possible to postpone or defer potentially high-risk disease modifying treatments.",
            "cite_spans": [],
            "section": "Recommendation",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Disease modifying therapies and their probable risk categories (https://cdn.ymaws.com/www.theabn.org/resource/collection/6750BAE6-4CBC-4DDB-A684-116E03BFE634/ABN_Guidance_on_DMTs_for_MS_and_COVID19.pdf)\n",
            "type": "table"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Natalizumab: A new treatment for relapsing remitting multiple sclerosis",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hutchinson",
                    "suffix": ""
                }
            ],
            "year": 2007,
            "venue": "Ther Clin Risk Manag.",
            "volume": "3",
            "issn": "2",
            "pages": "259-268",
            "other_ids": {
                "DOI": [
                    "10.2147/tcrm.2007.3.2.259"
                ]
            }
        },
        "BIBREF2": {
            "title": "Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Chun",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Hartung",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Clinical Neuropharmacology.",
            "volume": "33",
            "issn": "2",
            "pages": "91-101",
            "other_ids": {
                "DOI": [
                    "10.1097/WNF.0b013e3181cbf825"
                ]
            }
        },
        "BIBREF3": {
            "title": "Alemtuzumab in multiple sclerosis: mechanism of action and beyond",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Ruck",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Bittner",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wiendl",
                    "suffix": ""
                },
                {
                    "first": "SG",
                    "middle": [],
                    "last": "Meuth",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Int J Mol Sci.",
            "volume": "16",
            "issn": "7",
            "pages": "16414-16439",
            "other_ids": {
                "DOI": [
                    "10.3390/ijms160716414"
                ]
            }
        },
        "BIBREF4": {
            "title": "Mechanism of action of rituximab",
            "authors": [
                {
                    "first": "T",
                    "middle": [],
                    "last": "Cerny",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Borisch",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Introna",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Johnson",
                    "suffix": ""
                },
                {
                    "first": "AL",
                    "middle": [],
                    "last": "Rose",
                    "suffix": ""
                }
            ],
            "year": 2002,
            "venue": "Anticancer Drugs.",
            "volume": "13",
            "issn": "Suppl 2",
            "pages": "S3-10",
            "other_ids": {
                "DOI": [
                    "10.1097/00001813-200211002-00002"
                ]
            }
        },
        "BIBREF5": {
            "title": "Mechanism of siponimod: anti-inflammatory and neuroprotective mode of action",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Behrangi",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Fischbach",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Kipp",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Cells",
            "volume": "8",
            "issn": "1",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.3390/cells8010024"
                ]
            }
        },
        "BIBREF6": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "A pneumonia outbreak associated with a new coronavirus of probable bat origin",
            "authors": [
                {
                    "first": "P",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "XL",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "XG",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Nature.",
            "volume": "579",
            "issn": "7798",
            "pages": "270-273",
            "other_ids": {
                "DOI": [
                    "10.1038/s41586-020-2012-7"
                ]
            }
        },
        "BIBREF9": {
            "title": "",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Qin",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Tao",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Dysregulation of immune response in patients with COVID-19 in Wuhan",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "The chemistry of the Copaxone drug",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Arnon",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Sela",
                    "suffix": ""
                }
            ],
            "year": 1999,
            "venue": "Chem. Isr.",
            "volume": "1",
            "issn": "",
            "pages": "12-17",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Teriflunomide and its mechanism of action in multiple sclerosis",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Bar-Or",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Pachner",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Menguy-Vacheron",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Kaplan",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wiendl",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Drugs.",
            "volume": "74",
            "issn": "6",
            "pages": "659-674",
            "other_ids": {
                "DOI": [
                    "10.1007/s40265-014-0212-x"
                ]
            }
        },
        "BIBREF12": {
            "title": "The mechanism of action of interferon-\u03b2 in relapsing multiple sclerosis",
            "authors": [
                {
                    "first": "BC",
                    "middle": [],
                    "last": "Kieseier",
                    "suffix": ""
                }
            ],
            "year": 2011,
            "venue": "CNS Drugs.",
            "volume": "25",
            "issn": "6",
            "pages": "491-502",
            "other_ids": {
                "DOI": [
                    "10.2165/11591110-000000000-00000"
                ]
            }
        },
        "BIBREF13": {
            "title": "A review of the mechanisms of action of dimethylfumarate in the treatment of psoriasis",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Br\u00fcck",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Dringen",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Amasuno",
                    "suffix": ""
                },
                {
                    "first": "I",
                    "middle": [],
                    "last": "Pau-Charles",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Ghoreschi",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Exp Dermatol.",
            "volume": "27",
            "issn": "6",
            "pages": "611-624",
            "other_ids": {
                "DOI": [
                    "10.1111/exd.13548"
                ]
            }
        }
    }
}